Netanyahu says every encounter with Putin benefits Israel’s securityWorld August 23, 19:15
Netanyahu determined to prevent Iran from strengthening positions in SyriaWorld August 23, 18:21
Russia's military might on display at Army-2017 forumMilitary & Defense August 23, 18:20
Russian defense minister examines weapons seized from terrorists in SyriaMilitary & Defense August 23, 18:12
Grand Russian art exhibition to be held in Vatican in 2018Society & Culture August 23, 17:47
Argentinian footballer Emiliano Rigoni signs contract with Russia’s Zenit FCSport August 23, 17:36
German chancellor suggests exerting diplomatic pressure on North KoreaWorld August 23, 17:01
Russian Defense Ministry orbits satellite for inspecting military space apparatusMilitary & Defense August 23, 16:59
Israel supports Russia’s participation in Sobibor memorial project in PolandWorld August 23, 16:35
GENEVA, June 14. /TASS/. The Court of Arbitration for Sport announced on Tuesday that it would announce its decision regarding an appeal from Russian tennis player Maria Sharapova before July 18.
According to various media reports earlier in the day, tennis star Sharapova has filed an appeal with the CAS in Switzerland’s Lausanne against her two-year suspension, which was imposed last week by the International Tennis Federation’s (ITF) Tribunal over anti-doping violations.
"In her appeal to the CAS, Ms Sharapova seeks the annulment of the Tribunal’s decision to sanction her with a two-year period of ineligibility further to an anti-doping rule violation," the CAS said in its statement. "Ms Sharapova submits that the period of ineligibility should be eliminated, or in the alternative, reduced."
"The parties have agreed to an expedited procedure which will allow the CAS to render a decision, at the latest, on 18 July 2016," the statement added.
In early March, Sharapova announced that her doping tests revealed the presence of performance enhancing drug meldonium in the body system. Following the announcement, former World’s No. 1 was provisionally suspended from all tennis-related activities.
The drug meldonium (mildronate) was included in the list of preparations banned by WADA from January 1, 2016. The presence of the meldonium substance in the athlete’s blood during and between competitions is a violation of anti-doping rules. The substance belongs to S4 class on the WADA blacklist (hormones and metabolic modulators).
WADA announced on April 13 that the concentration of less than one microgram of meldonium in the body system of an athlete, whose doping tests were conducted before March 1, was acceptable.